Capmatinib: An overview of the latest clinical trial efficacy!

卡马替尼（Capmatinib）是一种针对MET蛋白激酶的抑制剂，主要用于治疗非小细胞肺癌（NSCLC）中的MET外显子14跳跃突变型。 METExon 14 skipping mutation is a mutation related to tumor growth and metastasis, and capmatinib inhibits the growth and spread of cancer cells by inhibiting the abnormal activation of the MET pathway.

Clinical trial data show that capmatinib has achieved significant efficacy in METExon14skipping mutantNSCLC patients. Here are some possible efficacy points:

1.Objective response rate (ORR): Clinical trials usually evaluate the degree of patient tumor response, that is, the objective response rate. Capmatinib has shown a higher objective response rate in patients with MET exon 14 skipping mutant NSCLC in some studies, which means that the patient's tumor has been significantly relieved during treatment.

2.Prolonged survival: Some clinical trials may involve assessing a patient’s overall survival (OS). Capmatinib has been shown to prolong patient survival in some studies, which has important clinical significance for improving patients' survival conditions.

3.Progression survival (PFS): Another important clinical endpoint is the patient's progression survival, which is the time during which the patient's disease no longer progresses during treatment. Capmatinib has shown a positive impact on survival from progression in some studies, suggesting that the drug can effectively control disease progression.

4.Safety and tolerability: In addition to efficacy, the safety and tolerability of capmatinib are also the focus of attention. In clinical trials, researchers typically monitor patients for adverse reactions and side effects during treatment. Taking these factors into consideration, the overall acceptability of capmatinib in patients can be assessed.

Overall, capmatinib showed potential efficacy in patients with METexon14skipping mutantNSCLC, providing this specific subgroup of patients with a treatment option that promises to improve survival and quality of life. However, any evaluation of a drug's efficacy should be based on the latest, comprehensive clinical trial data.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.